Hubei Guangji Pharmaceutical Co Ltd (000952) — Cash Flow-to-Debt Ratio
Hubei Guangji Pharmaceutical Co Ltd (000952) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥22.38 Million could theoretically repay 0% of its total liabilities (CN¥1.62 Billion) in one year. See 000952 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hubei Guangji Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Hubei Guangji Pharmaceutical Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see how efficiently does Hubei Guangji Pharmaceutical Co Ltd generate cash.
Annual Cash Flow-to-Debt Ratio for Hubei Guangji Pharmaceutical Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Hubei Guangji Pharmaceutical Co Ltd. Check 000952 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | CN¥60.43 Million | CN¥1.69 Billion | ▲ +9294.2% |
| 2024 | 0.00x | CN¥655.36K | CN¥1.72 Billion | ▲ +100.4% |
| 2023 | -0.09x | CN¥-148.96 Million | CN¥1.64 Billion | ▼ -297.3% |
| 2022 | 0.05x | CN¥45.08 Million | CN¥977.25 Million | ▼ -63.7% |
| 2021 | 0.13x | CN¥75.91 Million | CN¥598.09 Million | ▼ -34.8% |
| 2020 | 0.19x | CN¥119.38 Million | CN¥613.75 Million | ▲ +8.2% |
| 2019 | 0.18x | CN¥144.20 Million | CN¥802.21 Million | ▼ -36.9% |
| 2018 | 0.28x | CN¥231.44 Million | CN¥812.33 Million | ▲ +39.7% |
| 2017 | 0.20x | CN¥178.83 Million | CN¥876.65 Million | ▲ +19.0% |
| 2016 | 0.17x | CN¥167.07 Million | CN¥974.70 Million | ▲ +669.0% |
| 2015 | -0.03x | CN¥-33.35 Million | CN¥1.11 Billion | ▲ +56.6% |
| 2014 | -0.07x | CN¥-74.69 Million | CN¥1.08 Billion | ▼ -159.5% |
| 2013 | 0.12x | CN¥95.16 Million | CN¥816.78 Million | ▼ -14.2% |
| 2012 | 0.14x | CN¥108.02 Million | CN¥795.93 Million | ▲ +6.6% |
| 2011 | 0.13x | CN¥81.88 Million | CN¥643.07 Million | ▼ -10.1% |
| 2010 | 0.14x | CN¥77.18 Million | CN¥545.06 Million | ▲ +383.2% |
| 2009 | -0.05x | CN¥-24.35 Million | CN¥486.93 Million | ▼ -109.0% |
| 2008 | 0.56x | CN¥220.70 Million | CN¥395.78 Million | ▼ -45.3% |
| 2007 | 1.02x | CN¥331.98 Million | CN¥325.76 Million | ▲ +148.7% |
| 2006 | 0.41x | CN¥125.95 Million | CN¥307.34 Million | ▲ +165.5% |
| 2005 | 0.15x | CN¥54.14 Million | CN¥350.68 Million | ▲ +1909.2% |
| 2004 | -0.01x | CN¥-3.32 Million | CN¥388.76 Million | ▲ +80.5% |
| 2003 | -0.04x | CN¥-15.40 Million | CN¥352.38 Million | ▼ -118.0% |
| 2002 | 0.24x | CN¥76.20 Million | CN¥313.05 Million | ▲ +398.8% |
| 2001 | -0.08x | CN¥-22.40 Million | CN¥274.96 Million | ▼ -132.7% |
| 2000 | 0.25x | CN¥48.57 Million | CN¥194.67 Million | ▼ -27.4% |
| 1999 | 0.34x | CN¥68.57 Million | CN¥199.49 Million | ▲ +520.0% |
| 1998 | -0.08x | CN¥-15.29 Million | CN¥186.80 Million | — |